News: Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

105.10USD
11 Jul 2014
Price Change (% chg)

$-0.70 (-0.66%)
Prev Close
$105.80
Open
$106.00
Day's High
$106.00
Day's Low
$104.86
Volume
1,283,268
Avg. Vol
1,926,345
52-wk High
$106.74
52-wk Low
$85.50

Search Stocks
Select another date:

Mon, Jun 23 2014

Obama meets with CEOs of Goldman Sachs, others, on family issues

WASHINGTON - President Barack Obama met with Goldman Sachs Chief Executive Lloyd Blankfein, Johnson & Johnson chief Alex Gorsky and other business leaders on Monday to discuss ways to encourage companies to make their work places more family friendly.

Obama meets with CEOs of Goldman Sachs, others, on family issues

WASHINGTON, June 23 - President Barack Obama met with Goldman Sachs Chief Executive Lloyd Blankfein, Johnson & Johnson chief Alex Gorsky and other business leaders on Monday to discuss ways to encourage companies to make their work places more family friendly.

Medtronic to buy Covidien for $42.9 billion, rebase in Ireland

- U.S. medical device maker Medtronic Inc said on Sunday it had agreed to buy Covidien Plc for $42.9 billion in cash and stock and move its executive base to Ireland in the latest transaction aiming for lower corporate tax rates abroad.

J&J links up with GSK-led group on new two-drug HIV tablet

LONDON, June 12 - Johnson & Johnson has linked up with ViiV Healthcare - a specialist HIV company majority-owned by GlaxoSmithKline - to develop a new AIDS medicine combining two drugs in a single tablet.

Pharmacyclics, J&J drug shown to improve leukemia survival

CHICAGO - A new drug for the most common form of leukemia in adults improves survival for patients whose disease has worsened despite standard treatment, according to late-stage study findings released on Saturday.

UPDATE 1-Pharmacyclics, J&J drug shown to improve leukemia survival

CHICAGO, May 31 - A new drug for the most common form of leukemia in adults improves survival for patients whose disease has worsened despite standard treatment, according to late-stage study findings released on Saturday.

Pharmacyclics, J&J drug shown to improve leukemia survival

CHICAGO, May 31 - A new drug for the most common form of leukemia in adults improves survival for patients whose disease has worsened despite standard treatment, according to late-stage study findings released on Saturday.

China fines Johnson & Johnson and others for price fixing

BEIJING - Johnson & Johnson, Bausch & Lomb Inc and other major producers have been fined more than 19 million yuan ($3.04 million) for fixing prices in China's eye glass and contact lens market, China's top economic regulator said on Thursday.

China fines Johnson & Johnson and others for price fixing

BEIJING, May 29 - Johnson & Johnson, Bausch & Lomb Inc and other major producers have been fined more than 19 million yuan ($3.04 million) for fixing prices in China's eye glass and contact lens market, China's top economic regulator said on Thursday.

J&J sees device growth via new products, emerging markets

- Johnson & Johnson said on Thursday it would file for approvals of more than 30 major products by the end of 2016 as it looks to restore growth to a medical device division that has been overshadowed by its drugs business.

Select another date:
Search Stocks